Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Adial Pharmaceuticals ( (ADIL) ) has issued an update.
On January 5, 2025, Adial Pharmaceuticals announced that James W. Newman, Jr., a non-employee director and member of both the Audit Committee and the Compensation Committee, resigned from the company’s Board of Directors effective immediately. The company stated that Newman’s departure was not the result of any disagreement regarding Adial’s operations, policies, or practices, suggesting a routine governance change rather than a shift in strategic direction or indication of internal conflict for investors and other stakeholders.
The most recent analyst rating on (ADIL) stock is a Hold with a $0.22 price target. To see the full list of analyst forecasts on Adial Pharmaceuticals stock, see the ADIL Stock Forecast page.
Spark’s Take on ADIL Stock
According to Spark, TipRanks’ AI Analyst, ADIL is a Neutral.
The score is held down primarily by weak fundamentals (no revenue, ongoing losses, and persistent cash burn) and a bearish technical backdrop (below key moving averages with negative MACD). A modest positive offset comes from a low-leverage balance sheet and the recent $2.86M financing that supports near-term liquidity.
To see Spark’s full report on ADIL stock, click here.
More about Adial Pharmaceuticals
Adial Pharmaceuticals, Inc. operates in the biopharmaceutical industry, focusing on the development of prescription drugs targeting addiction and related disorders, with a particular emphasis on alcohol use disorder and other impulse control conditions.
Average Trading Volume: 453,394
Technical Sentiment Signal: Sell
Current Market Cap: $6.8M
For detailed information about ADIL stock, go to TipRanks’ Stock Analysis page.